At present, the commonly used immune checkpoint inhibitors (ICIs) for NSCLC include the PD-1 inhibitor nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab and durvalumab. The gene discussed is CD274; the disease is non-small cell lung carcinoma.